Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
RegulatoryapprovedVEPPANUPositive
AI Analysis
Summary
Rigel Pharmaceuticals announced FDA approval and commercial availability of VEPPANU (vepdegestrant), the first and only FDA-approved PROTAC therapy for adult patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer in the second line or later setting.
Outcome Details
VEPPANU is the first and only FDA-approved PROTAC for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer
Importance:8/10
Sentiment:
0.90
FDA approvalPROTACbreast canceradvanced/metastaticESR1-mutatedcommercial launch
Related Companies
Read the original article
Published by PR Newswire Pharma on August 13, 2026 12:05 PM